Close

Inhibikase Therapeutics (IKT) Reports First Patients Dosed in Phase 1 Clinical Trial of IkT-148009 to Treat Parkinson’s Disease and Related Disorders

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/19/2024

1. NFLX
2. INFY
3. ISRG
4. TSM
5. SPY
6. JWN
7. SLB
8. PPG
9. PARA
10. BX


Go back to Inhibikase Therapeutics (IKT) Reports First Patients Dosed in Phase 1 Clinical Trial of IkT-148009 to Treat Parkinson’s Disease and Related Disorders
(NASDAQ: IKT) Delayed: 2.10 --0 (-0%)
Previous Close $2.10    52 Week High $ 
Open $2.10    52 Week Low $ 
Day High $2.10    P/E N/A 
Day Low $2.10    EPS $ 
Volume 4